Medigene AG Cash Flow Conversion Efficiency

Latest as of June 2024: -0.180x

Medigene AG cash flow conversion efficiency. Based on the latest financial reports, Medigene AG (MDG1) has a cash flow conversion efficiency ratio of -0.180x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.54 Million ≈ $-4.14 Million USD) by net assets (€19.66 Million ≈ $22.98 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Medigene AG (2006–2023)

Cash flow conversion efficiency of Medigene AG from 2006 to 2023. This chart illustrates how Medigene AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. View MDG1 stock price and chart for real-time trading data and today's change.

Medigene AG Cash Flow Conversion Ratio Explained

Medigene AG cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Medigene AG Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Medigene AG ranked by their cash flow conversion efficiency. Also see Medigene AG stock valuation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
CAP-EX IRON ORE F:X0V	-0.025x
PALATIN TECHS DL-01 F:PTN	N/A
NOVRA TECHNOLOGIES INC. F:7CV	-0.231x
Diadrom Holding AB ST:DIAH	0.188x
Globavend Holdings Limited Ordinary Shares NASDAQ:GVH	0.038x
Kestrel Gold Inc V:KGC	-0.035x
Argent Biopharma Ltd AU:RGT	0.379x
WINDELN.DE SE INH O.N. F:WDL1	N/A

Annual Cash Flow Conversion Efficiency for Medigene AG (2006–2023)

The table below shows the annual cash flow conversion efficiency of Medigene AG from 2006 to 2023. Review cash generation quality of Medigene AG to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2023-12-31	€21.07 Million ≈ $24.63 Million	€-15.12 Million ≈ $-17.68 Million	-0.718x	-321.90%
2022-12-31	€37.03 Million ≈ $43.29 Million	€11.98 Million ≈ $14.00 Million	0.323x	+234.79%
2021-12-31	€44.82 Million ≈ $52.39 Million	€-10.75 Million ≈ $-12.57 Million	-0.240x	+48.54%
2020-12-31	€53.15 Million ≈ $62.14 Million	€-24.79 Million ≈ $-28.98 Million	-0.466x	-132.33%
2019-12-31	€81.82 Million ≈ $95.66 Million	€-16.42 Million ≈ $-19.20 Million	-0.201x	-112.60%
2018-12-31	€107.42 Million ≈ $125.59 Million	€-10.14 Million ≈ $-11.86 Million	-0.094x	+60.98%
2017-12-31	€86.17 Million ≈ $100.74 Million	€-20.85 Million ≈ $-24.37 Million	-0.242x	-406.02%
2016-12-31	€78.59 Million ≈ $91.88 Million	€-3.76 Million ≈ $-4.39 Million	-0.048x	+59.43%
2015-12-31	€89.99 Million ≈ $105.21 Million	€-10.61 Million ≈ $-12.40 Million	-0.118x	+33.95%
2014-12-31	€49.07 Million ≈ $57.37 Million	€-8.76 Million ≈ $-10.24 Million	-0.178x	+47.14%
2013-12-31	€36.28 Million ≈ $42.41 Million	€-12.25 Million ≈ $-14.32 Million	-0.338x	-129.38%
2012-12-31	€44.22 Million ≈ $51.69 Million	€-6.51 Million ≈ $-7.61 Million	-0.147x	-202.77%
2011-12-31	€47.93 Million ≈ $56.04 Million	€6.86 Million ≈ $8.02 Million	0.143x	+151.20%
2010-12-31	€40.80 Million ≈ $47.70 Million	€-11.41 Million ≈ $-13.34 Million	-0.280x	+23.34%
2009-12-31	€51.87 Million ≈ $60.64 Million	€-18.93 Million ≈ $-22.13 Million	-0.365x	+13.45%
2008-12-31	€64.91 Million ≈ $75.88 Million	€-27.36 Million ≈ $-31.99 Million	-0.422x	-35.63%
2007-12-31	€103.09 Million ≈ $120.53 Million	€-32.04 Million ≈ $-37.46 Million	-0.311x	-2564.08%
2006-12-31	€108.51 Million ≈ $126.86 Million	€-1.27 Million ≈ $-1.48 Million	-0.012x	--

About Medigene AG

XETRA:MDG1 Germany Biotechnology

Market Cap

$2.30 Million

€1.97 Million EUR

Market Cap Rank

#30065 Global

#2605 in Germany

Share Price

€0.13

Change (1 day)

+0.00%

52-Week Range

€0.13 - €0.13

All Time High

€36.05